In a patient with potential rabies exposure, how should a rabies‑specific monoclonal antibody (Rabishield) be administered and dosed as part of post‑exposure prophylaxis?

Rabies Monoclonal Antibody (Rabishield) Administration and Dosing

For post-exposure prophylaxis in previously unvaccinated patients, administer rabies-specific monoclonal antibody at 20 IU/kg body weight on day 0, infiltrating the entire calculated dose into and around all wounds when anatomically feasible, with any remaining volume given intramuscularly at a site distant from the vaccine injection, combined with a 4-dose rabies vaccine series on days 0,3,7, and 14. 1, 2

Dosing Calculation and Administration

• Calculate the dose as 20 IU/kg body weight for all patients regardless of age, using the same weight-based formula universally applied to human rabies immune globulin (HRIG) 1, 2

• Administer on day 0 (the day of first vaccine dose), ideally simultaneously with the first rabies vaccine to provide immediate passive immunity while vaccine-induced antibodies develop over 7-10 days 1, 2

• Infiltrate the entire calculated dose thoroughly into and around every wound site whenever anatomically feasible—this local wound infiltration is critical, as rare PEP failures have been linked to inadequate wound infiltration 1, 2

• Inject any remaining volume intramuscularly at a site distant from the vaccine injection site—never use the same syringe or anatomical site as the vaccine, as co-administration interferes with active antibody production 1, 2

Evidence Supporting Monoclonal Antibody Use

The most recent high-quality evidence demonstrates that rabies monoclonal antibodies are non-inferior to HRIG:

• A 2023 phase III trial of ormutivimab (n=720) showed non-inferiority to HRIG, with an adjusted geometric mean concentration ratio of 1.01 (95% CI: 0.91-1.14) on day 7, and the monoclonal antibody group actually demonstrated higher seroconversion rates on days 7,14, and 42 3

• A 2018 phase 2/3 study (n=199) demonstrated that SII RMAb produced a day 14 GMC ratio of 4.23 (96.9% CI: 2.59-6.94) relative to HRIG, with a GMC of 24.90 IU/mL for the monoclonal antibody versus 5.88 IU/mL for HRIG, establishing both safety and superior neutralizing antibody production 4

• Monoclonal antibodies offer significant advantages over polyclonal immunoglobulin: consistent potency, no risk of blood-borne pathogen transmission, unlimited supply potential, and potentially lower interference with vaccine-induced immunity 4, 3

Critical Timing Considerations

• If not administered on day 0, the monoclonal antibody can still be given up to and including day 7 after the first vaccine dose without compromising protection 1, 2

• Do not administer after day 7—vaccine-induced antibodies are presumed to have developed by then, and additional passive antibody may suppress the active immune response 1, 2

• The 7-day window exists because active antibody response to rabies vaccine requires approximately 7-10 days to develop, and passive antibody bridges this critical gap 1

Dosing Limits and Safety

• Never exceed 20 IU/kg—higher doses have been shown to partially suppress vaccine-induced antibody production and may compromise protection 1, 2

• Monoclonal antibodies demonstrate excellent safety profiles, with local injection site pain reported in <40% of subjects and no fever, induration, redness, or swelling in phase I trials 5

• Most adverse reactions are mild to moderate in severity, comparable to or better than HRIG 4, 3

Complete PEP Regimen

• Immediate wound washing with soap and water for 15 minutes is the single most effective measure for preventing rabies infection and must precede all other interventions 1

• Administer 1.0 mL rabies vaccine (HDCV or PCECV) intramuscularly on days 0,3,7, and 14 in the deltoid muscle for adults and older children, or anterolateral thigh for young children—never use the gluteal area, as this produces inadequate antibody response 1

• This combined regimen (monoclonal antibody + vaccine) is nearly 100% effective when administered promptly and appropriately 1

Special Populations

• Previously vaccinated individuals require only 2 vaccine doses (days 0 and 3) and should NOT receive any passive immunoglobulin or monoclonal antibody, as it will inhibit the anamnestic antibody response 1, 2

• Immunocompromised patients require a 5-dose vaccine regimen (days 0,3,7,14, and 28) plus the monoclonal antibody at 20 IU/kg on day 0, with mandatory serologic testing 1-2 weeks after the final dose to confirm adequate response 1

Common Pitfalls to Avoid

• Failure to infiltrate wounds with the full calculated dose—this is the most critical error and has been linked to rare PEP failures 1, 2

• Administering passive antibody to previously vaccinated persons—this suppresses the memory immune response and is contraindicated 1, 2

• Using the gluteal area for vaccine administration—this site produces inadequate antibody response and is associated with vaccine failure 1

• Delaying treatment while awaiting animal observation results—initiate PEP immediately in rabies-endemic areas and discontinue only if the animal remains healthy after 10 days 1